163 results on '"Shimoji, Masaki"'
Search Results
2. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
3. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
4. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
5. Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer
6. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
7. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
8. The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery
9. Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer
10. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
11. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion
12. Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis
13. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma
14. Data from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
15. Supplementary Figure 1B from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
16. Supplementary Figure 2 from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
17. Supplementary Table 1 from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
18. Supplementary Figure Legend from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
19. Supplementary Figure Legend from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
20. Supplementary Figure 1 from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
21. Supplementary Table 1 from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
22. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
23. Recent evidence, advances, and current practices in surgical treatment of lung cancer
24. Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
25. Additional file 1 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
26. Dichotomous preferences and the possibility of Arrovian social choice
27. Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
28. Seeds-Needs Cooperation Method in Development of Nursing Care Robots: Utilization of Embodiment Model with Device Functions Simplified by ICF Model
29. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
30. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: A novel ALK fusion gene?
31. A clinicopathological and immunohistological re-evaluation of adenosquamous carcinoma of the lung
32. A case of intrapulmonary solitary fibrous tumor harboring NAB2-STAT6 fusion gene
33. Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
34. Approach to Development of a Nursing Care Robot at Okinawa Prefectural Council for Needs-Seeds Cooperation on Nursing Care Robots
35. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
36. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
37. Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions
38. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
39. Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer
40. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
41. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
42. P1.02-047 Effect of Dasatinib on EMT-Mediated-Mechanism of Resistance against EGFR Inhibitors in Lung Cancer Cells
43. P3.02b-120 EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib
44. Prognostic impact of pleural lavage cytology in patients with primary lung cancer
45. Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation
46. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
47. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer
48. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
49. Pulmonary adenosquamous carcinoma with mucoepidermoid carcinoma-like component with characteristic p63 staining pattern: Either a novel subtype originating from bronchial epithelium or variant mucoepidermoid carcinoma
50. EGFRT790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.